Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Upgraded Software Enhances Confidence in Flow Cytometry for Hematology Labs

By BiotechDaily International staff writers
Posted on 20 May 2013
An innovative software solution, with cutting-edge image analysis technology for use with a specialized 5-color reagent, has been upgraded to further enhance the performance of flow cytometry in hematology laboratories.

Beckman Coulter Inc. (Pasadena, CA, USA) introduces an advanced version of the innovative “CytoDiff CXP” Autogating Software. The software is an integral part of the company’s unique HematoFlow solution1 —combining diagnostic reagent, hematology and flow cytometry hardware, and IT expertise.

The introduction of Version 2 CytoDiff CXP Autogating software is designed to provide added confidence in the use of flow cytometry in the routine hematology lab for the autovalidation of abnormal samples. Easy-to-use, the advanced Version 2 software further improves sub-population classifications. New features include greater precision in the removal of potential interference and metrics that provide a new “confidence level” on population classification. The new software simplifies the review process, making it easier to validate results with greater certainty.

HematoFlow with the CytoDiff five-color antibody cocktail and CXP Autogating Software make it possible to use the precision of flow cytometry to deliver extended white blood cell (WBC) differential results with far greater consistency than manual microscopic assessment. The CytoDiff five-color antibody cocktail uses six monoclonal antibodies to establish the differential. “HematoFlow with CytoDiff CXP Autogating Software offers enhanced performance by delivering flow cytometry expertise alongside cutting edge image analysis technology applied to each of the multiple population classifiers,” explained Dr. Josee Naegelen, hematology marketing manager, Beckman Coulter Diagnostics Global Product Management and Strategy.

“The routine use of flow cytometry for validating abnormal samples can improve workflow and turnaround time as well as providing access to additional diagnostic information for patients,” said Dr. Naegelen. “This has a significant impact on the lab, enabling it to handle increasing workloads with greater confidence.”

Laboratories are already working with Beckman Coulter to increase confidence in the routine use of flow cytometry in the hematology process for validating abnormal samples. Hospitals including University Hospital, Rennes and Bordeaux (France), Erasme University Hospital, Brussels (Belgium), and several private labs are successfully adopting this approach. They are using Beckman Coulter’s FC 500 flow cytometer and the CytoDiff reagent to establish the extended flow WBC differential, detecting and quantifying normal and abnormal population subsets.

[1] CytoDiff is not available in the United States and other geographies.

Related Links:

Beckman Coulter



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: The new peptide offers a triple hormone effect in a single-cell molecule (Photo courtesy of Indiana University).

Tripeptide Drug Effectively Controls Metabolic Syndrome in Rodent Model

Promising results in reducing obesity and normalizing glucose metabolism obtained with a synthetic dipeptide drug have been enhanced by the addition of a molecule of a third hormone, glucagon.... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.